Rutgers University Study of the Genetics of Blood Cancers

NCT07714044 | Not Yet Recruiting

• 1 other identifier: Pro2026000226
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variants associated with leukemia, lymphoma, myeloma and other blood cancers.

Conditions

Blood Cancers; Blood Cancer; Leukemia; Lymphoma; Myeloma; Hematologic Cancer; Hematologic Malignancies; Hematologic Neoplasm; Hematologic Tumors

Keywords

genetics; blood cancer; blood cancers; leukemia; lymphoma; myeloma; hematologic cancer; hematologic malignancy; hematologic tumor; hematologic neoplasm

Outcome Measures

Primary Outcomes (1)

• Genetic risk variants associated with blood cancer

  Genetic factors will be measured through whole exome sequencing and genome-wide genotyping array, and then correlated with blood cancer subtype.

  2 years

Study Arms (2)

Cases

Persons with blood cancer

Controls

Persons who do not have blood cancer

Eligibility Criteria

• Age: 18 Years - 110 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of anyone at least 18 years old who lives in the United States, including both individuals who have or had blood cancer and those who have not. Participants include males, females, non-binary, and all race-ethnic groups.

You may qualify if:

• age 18 years or older
• currently living in the United States
• have access to the internet and a computer, laptop, tablet or smartphone
• willing to provide written informed consent for participation
• willing to provide DNA via a saliva sample using a collection kit mailed to your home
• willing to complete a survey with questions about health related to the study of blood cancer.

Sponsors & Collaborators

• Rutgers, The State University of New Jersey: lead

Study Sites (1)

Rutgers University

Piscataway, New Jersey, 08854, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Saliva sample

MeSH Terms

Conditions

Hematologic Neoplasms; Leukemia; Lymphoma; Neoplasms, Plasma Cell

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Tara Matise, PhD

  Rutgers University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Tara Matise, PhD

CONTACT

848-445-3125; rugcc@rutgers.edu

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Distinguished Professor

Study Record Dates

• First Submitted: July 15, 2026
• First Posted: July 20, 2026
• Study Start: August 1, 2026
• Primary Completion (Estimated): August 1, 2029
• Study Completion (Estimated): August 1, 2029
• Last Updated: July 20, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)